Whether Detection of Gene Mutations Could Identify Low- or High-Risk Papillary Thyroid Microcarcinoma? Data from 393 Cases Using the Next-Generation Sequencing
Table 5
Patient characteristics of 320 PTMC divided into low- and high-risk groups.
Total
Low-risk
High-risk
n = 320
n = 102
n = 218
Gender
M
86 (26.9%)
24 (23.5%)
62 (28.4%)
0.417
F
234 (73.1%)
78 (76.5%)
156 (71.6%)
Age at diagnosis (years)
43.4 ± 11.9
44.2 ± 11.7
43 ± 11.7
0.389
Maximum tumor size (mm)
Mean ± SD
6.4 ± 2.3
5.6 ± 2.2
6.8 ± 2.3
<0.001
≤5
118 (35%)
53 (52.0%)
65 (29.8%)
<0.001
>5
202 (65%)
49 (48.0%)
153 (70.2%)
Chronic lymphocytic thyroiditis
Yes
56 (17.5%)
17 (16.7%)
39 (17.9%)
0.875
No
264 (82.5%)
85 (83.3%)
179 (82.1%)
Staging (VIII ed. TNM)
I
295 (92.2%)
102 (100%)
193 (88.5%)
<0.001
II
25 (7.8%)
0
25 (11.5%)
Tumor recurrence
Yes
7 (2.2%)
1 (1.0%)
6 (2.8%)
0.437
No
311 (97.2%)
101 (99.0%)
210 (96.3%)
0.281
n.a.
2 (0.6%)
0
2 (0.9%)
1.000
BRAF
Wt.
55 (17.2%)
15 (14.7%)
40 (18.3%)
0.525
V600E
265 (82.8%)
87 (85.3%)
178 (81.7%)
KRAS
wt.
318 (99.4%)
101 (99.0%)
217 (99.5%)
0.537
Q61K
2 (0.6%)
1 (1.0%)
1 (0.5%)
NRAS
wt.
319 (99.7%)
101 (99.0%)
218 (100%)
0.319
Q61R
1 (0.3%)
1 (1.0%)
0
RET/PTC
wt.
312 (97.5%)
100 (98%)
212 (97.2%)
1.000
RET/PTC1
5 (1.6%)
2 (2%)
3 (1.4%)
0.655
RET/PTC3
3 (0.9%)
0
3 (1.4%)
0.554
BRAF + NRAS
Yes
1 (0.3%)
1 (1.0%)
0
0.319
No
319 (99.7%)
101 (99.0%)
218 (100%)
BRAF + RET/PTC
Yes
3 (0.9%)
1 (1.0%)
2 (0.9%)
1.000
No
317 (99.1%)
101 (99%)
216 (99.1%)
wt: wild type, na: not available, and PTMC: papillary thyroid microcarcinoma. The high-risk PTMC was defined as having one or more advanced characteristics including multifocality, extrathyroidal extension (ETE), intrathyroid spread, and LN metastasis, whereas the low-risk PTMC has none of these features. Data are expressed as mean ± SD or absolute number (%). Comparison between low-risk and high-risk groups was performed by ANOVA or chi-square test when appropriate. Significant differences are shown in bold characters .
